Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2928920 | 1.00 | PLCG1 (0.33) | PLCG1RAB9AL3MBTL1HTT | |
| SCHEMBL2928917 | 1.00 | PLCG1 (0.33) | PLCG1RAB9AL3MBTL1HTT | |
| SCHEMBL3598857 | 0.90 | PLCG1 (0.32) | PLCG1RAB9AL3MBTL1HTT | |
| SCHEMBL3598856 | 0.90 | PLCG1 (0.32) | PLCG1RAB9AL3MBTL1HTT | |
| SCHEMBL2923293 | 0.88 | PLCG1 (0.33) | PLCG1RAB9AL3MBTL1HTT | |
| SCHEMBL4258695 | 0.83 | CXCR3 (0.34) | PLCG1RAB9AL3MBTL1 | |
| SCHEMBL6702522 | 0.83 | PLCG1 (0.35) | PLCG1RAB9A | |
| SCHEMBL3049029 | 0.83 | PLCG1 (0.35) | PLCG1RAB9A | |
| SCHEMBL6702524 | 0.83 | PLCG1 (0.35) | PLCG1RAB9A | |
| SCHEMBL3585090 | 0.82 | POLB (0.32) | PLCG1L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1499620-B1 | PROCESS FOR PREPARING 6-ALKYLIDENE PENEM DERIVATIVES | WYETH CORP (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20060074064-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH (US) | 2006-04-06 | — | — | US | disclosed |
| US-7018997-B2 | Tricyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH (US) | 2006-03-28 | — | — | US | disclosed |
| US-20040043978-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074064-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, MGAM, PREP | PLCG1 2494/4885RAB9A 2490/4885L3MBTL1 661/4885 |
| US-20040043978-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, MGAM, PREP | PLCG1 2469/4885RAB9A 2292/4885L3MBTL1 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.